The ancient biochemical 5-hydroxytryptamine—also known as 5-HT and serotonin—has been controlled through evolution to be used widely across the plant and animal kingdoms.
5-HT is used by mammals as a neurotransmitter within the peripheral and central nervous systems. It is also used as a local hormone by many other tissues, such as immune cells, the cardiovascular system and the gastrointestinal tract. Due to this multiplicity of function, 5-HT is implicated in a wide range of pathological and physiological processes. This vast number of roles has led to the development of a number of compounds of therapeutic value, such as numerous antiemetic, antipsychotic and antidepressant drugs.
5-HT has the ability to mediate an array of actions and this is partly due to the vast number of 5-HT receptor families and subtypes that have evolved1. At present, 18 genes have been identified, which encode 14 discrete mammalian 5-HT receptor subtypes that are separated into seven families, all but one of which are part of the G-protein coupled receptor (GPCR) superfamily. The 5-HT3 receptor is a Cys-loop ligand-gated ion channel (LGIC) that evolved independently of the GPCR 5-HT receptors together with other members of this superfamily (for example GABAA receptor, nicotinic acetylcholine receptor, Zn2+-activated receptor and glycine receptor). Additional receptor heterogeneity is produced through RNA editing (the 5-HT2C receptor), alternative splicing (for example 5-HT3, 5-HT4 and 5-HT7 receptors), and the putative formation of heterodimers and homodimers (5-HT4 and the β2 adrenoceptor receptor)2.
The 5-HT1 Receptor Family
This family includes five individual gene products: 5-HT1A, 5-HT1B, 5-HT1D, 5-ht1e, and 5-HT1F receptors.
Previous, some of these receptors were believed to be species-specific homologs (for example, the 5-HT1D receptor in humans and 5-HT1B receptor in rats). However, the genes for each of these receptors are now known to exist in all mammalian species investigated to date. Each receptor is encoded by one, intron-less reading frame and they share significant sequence homology. All 5-HT1 family receptors couple to Gi/o to inhibit adenylyl cyclase and lower cAMP levels, however, alternative signal transduction mechanisms have also been elucidated. While the molecular properties and gene structure of these receptors are analogous, discrete patterns of regional expression in the body and major cellular variations underlie divergent physiological traits. A number of these receptors are known to be autoreceptors that control the release of serotonin and the excitability of serotonin neurons3. However, these receptors are also expressed in nonserotonergic neurons, where they can have similar impacts on other neurotransmitters.
5-HT1A receptors are widely distributed in the CNS, where they can also be found in the dendrites, soma, and in certain cases the axon hillock of neurons, and astrocytic cell body and processes. The 5-HT1A receptor is expressed by several nonserotonergic neurons (as heteroreceptors) and by all serotonin neurons (as autoreceptors). When the 5-HT1A receptor is activated, its electrophysiological effect on neurons is usually inhibitory and acts by decreasing the neuronal firing rate.
Several highly selective ligands have been created, and they range from partial agonists to full agonists, inverse agonists, and antagonists. It is believed that 5-HT1A receptors are the therapeutic targets for a number of neuropsychiatric disorders such as schizophrenia, depression, and anxiety. Clinically used ligands of 5-HT1A receptor include some of the atypical antipsychotics, which have have neutral antagonist or partial agonist activity, and buspirone, a partial agonist used for generalized anxiety disorder. 5-HT1A receptor partial agonists are anxiolytic drugs that are clinically useful and could act on the autoreceptors to decrease serotonergic activity, while 5-HT1A receptors in the hippocampus region have been implicated in the regulation of the hypothalamic-pituitary-adrenal axis and in the mechanism of antidepressant action (by promoting neurogenesis).
Serotonin syndrome, hyperphagia, and hypothermia are other physiological effects of activation of the CNS 5-HT1A receptor1. 5-HT1A receptor knockout mice were found to have heightened anxiety and can display reduced depression-like features4,5. Just like the other serotonin receptors, this could involve receptor actions during the early development of the brain and also during the processing of emotional experience in the adult.
Several highly selective ligands for 5-HT1A receptors have been developed, but it must be noted that some of these share affinity for 5-HT7 receptors (for example, 8-OH-DPAT) or for other 5-HT1 subtypes or 5-HT2 receptors. Most often, WAY 100635 has been utilized as a highly selective 5-HT1A receptor neutral antagonist, while selective agonists include S-14506 and Xaliproden.
Similar to 5-HT1A receptors, 5-HT1B receptors are also widely distributed in the CNS in nonserotonergic and serotonergic neurons. These receptors are mainly translocated to axon terminals: hence there is an anatomical discrepancy between the mature 5-HT1B receptor protein and the localization of mRNA. The 5-HT1B receptor was originally assumed to be the rat analog of 5-HT1D receptors however, it is now evident that both types of receptors exist in all mammalian species inspected so far and that their regional distributions also vary6. β-adrenergic antagonists possess high affinity for 5-HT1B receptors only in some species and not all.
5-HT1B autoreceptors reduce 5-HT synthesis and release and improve reuptake through the serotonin transporter (SERT). In addition, 5-HT1B heteroreceptors suppress the release of many different neurotransmitters, based on the types of neurons expressing them. When 5-HT1B receptor agonists are systemically administrated, they lead to a number of behavioral effects such as decreased aggression, changes in brain reward mechanisms, and increased locomotion, while selective antagonists may have certain pro-cognitive potential7,8. When these receptors are expressed in different and possibly competing sets of neurons this may have an impact on their utility as a clinical target, albeit many 5-HT1B/D receptor agonists are known to be effective as anti-migraine treatments.
5-HT1B receptor knockout mice have been widely tested and have a clear phenotype defined by increased aggression and a predisposition for addiction-like behaviors, in the majority of cases. However, the phenotype of these mice may rely on compensatory changes in the dopamine system during the course of development instead of being caused by reduced 5-HT1B receptor signaling in adults.
Many moderately selective agonists, including the more brain-penetrant CP 94253 as well as CP 93129, have been developed, and antagonists like SB 224289 are generally used for identifying 5-HT1B receptor-mediated responses.
Compared to 5-HT1B receptors, 5-HT1D receptors are expressed at more modest levels in the brain. However, the largest extent of expression appears to be in the raphe nuclei. Similarly, 5-HT1D receptor binding sites exist at a lower level when compared to 5-HT1B receptor binding sites in the majority of the brain regions9. Most of the evidence, utilizing 5-HT1B receptor knockout mice as controls, denotes that the activity of terminal serotonin autoreceptors in the forebrain region is of the 5-HT1B receptor type10. However, there may be somatodendritic 5-HT1D autoreceptors that mediate the release of serotonin inside the raphe nuclei11.
The problem for the majority of putative selective 5-HT1D receptor ligands is that they have a high affinity for more than a single receptor, often either the 5-HT1A or 5-HT1B receptors, but usually not both. For example, ketanserin has about 100-fold higher affinity for human 5-HT1D when compared to 5-HT1B receptors, but it also has the highest affinity for 5-HT2A receptors. This enables drug combinations to attain conditions that are rationally selective for inhibition or activation of 5-HT1D receptors.
The lower case letters in the 5-ht1e receptors indicate that it has not been established to have meaningful physiological functions in vivo.
The existence of the 5-ht1e receptor was initially hypothesized on the basis of radioligand binding studies utilizing brain homogenates, demonstrate a 5-HT1-like receptor with low affinity for 5-carboxamidotryptamine. It is now evident that a number of binding sites could have contributed to this observation. For the 5-ht1e receptor, the gene sequence has been cloned from a guinea pig brain genomic DNA and human placental library but has not been detected in mouse and rat12.
Only a few pharmacological studies of this receptor have been performed in human tissue or in rodents, but despite this fact, it was identified by RT-PCR in numerous regions of guinea pig, and in the monkey and human brains through in-situ hybridization6. Moreover, highly selective ligands have not been developed, albeit several typical 5-HT1 receptor antagonists and agonists exhibit modest affinity at these receptors in heterologous expression systems. A new technique for labeling 5-ht1e binding sites in guinea pig was recently developed and this strategy may be useful for modeling human 5-ht1e receptors13. The physiological importance of this receptor continues to be vague.
Detected in various species, the 5-HT1F receptor has been cloned from mouse, guinea pig, rat, and human genomes. This receptor, similar to other members of the 5-HT1 receptor family, suppresses adenylyl cyclase activity through a Gi-dependent mechanism. The 5-HT1F receptor is expressed at modest levels in the CNS on both non-serotonergic and serotonergic cell bodies where it behaves as a heteroreceptor and autoreceptor, respectively.
Similar to 5-HT1B receptors, 5-HT1F receptors are expressed in vestibular nuclei and trigeminal ganglion neurons and have a high affinity for triptan drugs that are useful for treating migraine headache. The corresponding contribution of each of these two receptors to pain relief in migraine headaches has not been resolved yet. Less selective agonists that could bind multiple 5-HT1 receptors (for example, 5-HT1B/D/F subtypes, like the “triptans”) may alleviate migraine headaches through numerous mechanisms; hence, more selective drugs may have distinct side-effect profiles and clinical efficacy. For instance, the 5-HT1F receptor agonist LY 334370 is relatively selective and has about 100-fold higher affinity for 5-HT1F over 5-HT1B receptors. Although active in animal models of anti-migraine activity, this compound appears to act on the trigeminal nucleus rather than through a vascular mechanism.14 No selective 5-HT1F antagonists have been developed thus far.
The 5-HT2 Receptor Family
5-HT2A, 5-HT2B, and 5-HT2C receptors are the three members of the 5-HT2 family. The pharmacological importance of these receptors is substantial owing to their complex pharmacological features and clinical significance. 5-HT2 receptors were initially theorized based on a significant study performed by Picarelli and Gaddum in 195715. With the help of a guinea pig ileum contraction bioassay, the duo identified two classes of “tryptamine” receptors (called “M” and “D”) corresponding to 5-HT2 and 5-HT3 receptors in present nomenclature.
Analogous sequence homology, overlapping pharmacology, and structural motifs are shared by the members of the 5-HT2 receptor family, although highly selective ligands are available and significant ligand development has taken place16. Multiple signal transduction pathways, agonist-directed signaling, prominence of inverse agonists, and significant clinical roles in neuropsychiatric conditions some of the remarkable features of these receptors. The 5-HT2 receptors—similar to 5-HT1 receptors—have a seven-transmembrane domain motif but they have a tendency to conjugate with phospholipases C and A2. Moreover, the relative efficiency of coupling to these effectors differs based on the type of cell being studied.
Densely expressed in the forebrain, specifically the cortex, 5-HT2A receptors are expressed in both pyramidal neurons and interneurons. Complex pharmacological patterns of activity are displayed by numerous ligands at 5-HT2A receptors, spanning from full agonism to partial agonism, and also from neutral antagonism to inverse agonistic behavior.
It is believed that these different activities reflect ligand stabilization of various structural conformations, which have been successfully resolved by X-ray crystallography in certain cases. In addition, site-directed mutagenesis has been used for testing structure-activity models. Through the heterologous expression of 5-HT2A receptors and molecular strategies, a large amount of biophysical data has been created. Concurrent analysis of numerous signal transduction mechanisms in cell culture systems has also demonstrated that the same ligand can have varying degrees of intrinsic activity for activating different second messenger systems by the same 5-HT2A receptor population17. This additionally supports the concept of dynamic and complex structure-activity relationships for 5-HT2C and 5-HT2A receptors.
Compared to other 5-HT receptors, 5-HT has low affinity for the 5-HT2A receptor, with a Kd being in the low micromolar range. Nevertheless, it can be debated that the active and high-affinity conformational state has about ten-fold higher affinity for the 5-HT2A receptor. A number of agonists, including LSD and DOI, have a high affinity for 5-HT2A receptors and others show selective potency for triggering one signal transduction pathway over another (for example, TCB-2). However, these compounds are not specifically selective because they also bind to other 5-HT2 receptors. Many well-characterized antagonists show high selectivity for 5-HT2A receptors, including MDL 100907 and ketanserin. While several others have high affinity, their specificity is not completely described. There are certain 5-HT2A receptor agonists that create psychotomimetic effects (LSD is the most well-known), and hence many antipsychotic medications are high-affinity 5-HT2A receptor antagonists.
Although 5-HT2B receptors are sporadically expressed in district subregions of CNS, they are densely expressed in heart, kidney, liver and the fundus of the stomach. This pattern of expression is different from 5-HT2C and 5-HT2A receptors, which are expressed at comparatively higher levels in the CNS. These receptors share affinity for many of the same kinds of drugs, but only a few highly selective 5-HT2B receptor antagonists, including RS 127445, have been described. Although the physiological role of 5-HT2B receptors is still vague, they have been implicated in anxiety, morphogenesis, and cardiac function. Despite the fact that 5-HT2B receptors have analogous signal transduction coupling to other 5-HT2 receptors in vitro, not much evidence has been generated for endogenous receptors.
5-HT2C receptors are expressed at low levels beyond the brain, but they are robustly expressed across the CNS. Among 5-HT receptors, 5-HT2C receptors are considered to be special because the mRNA transcript can be edited, causing slight changes in coding sequence that can have functionally pertinent influences on the mature receptor protein18. 5-HT2C receptor knockout mice have been created which remarkably develop seizures, glucose intolerance, and mid-life obesity19.
The 5-HT2C receptors’ pharmacology is akin to that of the other 5-HT2 receptors; 5-HT2C receptors show intricate interactions with agonist-directed signaling, signal transducing mechanisms, and inverse agonism by a few atypical antipsychotics. Data from animal models denotes that 5-HT2C receptors may impact on addiction, appetite, anxiety, and antipsychotic drug actions. SB 242084 is considered a fairly selective 5-HT2C receptor antagonist with anxiolytic activity. No highly selective 5-HT2C agonists have been developed so far because those that were described also have affinity for other 5-HT2 receptors. Lorcaserin shows some selectivity for the 5-HT2C receptor, even though no readily available sources are there for this kind of molecule beyond custom synthesis20.
The 5-HT3 Receptor
The 5-HT3 receptor is the sole 5-HT receptor that belongs to the Cys-loop ligand-gated ion channel (LGIC) family21. This receptor is believed to be a pentameric complex, which is consistent with other family members of the Cys-loop LGICs22. The receptor complex may consists of a mix of up to five varied subunits called 5-HT3A-E, although only the 5-HT3B and 5-HT3A subunits have been comprehensively examined. The 5-HT3 receptor complex—a non-selective cation channel (most permeable to K+, Na+, and Ca2+ ions)—facilitates rapid synaptic depolarizing neurotransmission in the brain and is liable to fast desensitization. Current attention is on the combination of subunits that form the functional channel in native tissue.
Within the recombinant systems, the expression of the 5-HT3A subunit alone creates a functional receptor that shows several properties of native receptors. The limitation is that a relatively high conductance single-channel receptor cannot be generated by homomeric 5-HT3A receptors, something that is obvious in certain populations of native neuronal receptors. Most importantly, co-expression of the 5-HT3B and 5-HT3A subunits leads to a heteromeric receptor that imitates the high conductance of certain populations of native receptors in a more faithful manner23,24. Apart from 5-HT, the action of 5-HT3 receptor is modulated allosterically through volatile alcohols and anesthetics25,26,27. However, the actions of these compounds may rely on the receptor’s subunit composition.28
The highest densities of 5-HT3 receptors within the brain are within brainstem nuclei covering the chemoreceptor trigger zone—to be precise, the dorsal motor nucleus of the vagus nerve, nucleus tractus solitaries, and area postrema29. Expression of the 5-HT3 receptor is also evident in human forebrain regions such as the caudate-putamen, amygdala, and hippocampus30. Importantly, expression within the extrapyramidal system (substantia nigra and caudate-putamen [striatum]) cannot be readily identified in other species (like rodents and/or non-human primates).
Within the 5-HT3 receptor complex, the 5-HT binding site is formed by neighboring N-termini from adjacent subunits present in the pentameric complex. Through structural analysis, three peptide loops (labeled as A, B, and C) has been found to occur from the “principal” subunit, and an additional three peptide loops from the “complementary” subunit (D, E, and F) take part in ligand binding. Therefore, the initial report regarding the stoichiometry of the heteromeric 5-HT3AB receptor (with B-A-B-B-A as subunit composition) created a great deal of debate about the potential to detect pharmacological compounds that would differentiate heteromeric 5-HT3AB receptors from homomeric 5-HT3A receptors. The former’s binding sites would emerge from A-A interfaces, while this structural interface was not present in heteromeric 5-HT3AB receptors. However, the B-A-B-B-A stoichiometry has been questioned recently31.
Most of the compounds examined so far fail to differentiate between molecular isoforms of the 5-HT3 receptor. Picrotoxin is a notable exception which shows weak (micromolar) affinity but excellent selectivity (about 100-fold for homomeric mouse 5-HT3A against heteromeric mouse 5-HT3AB receptors)32. This has been shown in functional recordings, and the molecular interaction could be a channel blockade of the 5-HT3 receptor instead of competition at the 5-HT binding site.
While the search goes on for compounds that readily differentiate between 5-HT3 receptor molecular isoforms, there are a vast number of ligands that exhibit high selectivity for the 5-HT3 receptor against other neurotransmitter receptors. Apart from antagonists, high affinity and selective agonists are also available for the 5-HT3 receptor, albeit these are likely to be partial agonists similar to methyl-5-HT—the non-selective exogenous agonist. mCPBG, PBG, and pumosetrag (DDP733) are a few examples of partial agonists, and SR 57227A is a classic example of an exogenous near full agonist.
The release of numerous neurotransmitters, including facilitation of GABA, dopamine, and 5-HT release, is modulated by the activation of the 5-HT3 receptor, even though the receptor is not believed to be expressed by 5-HT neurons34,35. On the other hand, the 5-HT3 receptor has an inhibitory impact on acetylcholine release in the cortex36,37, which could be mediated through GABAergic interneurons37,38.
Several 5-HT3 receptor ligands, such as palonosetron, tropisetron, granisetron, and ondansetron, have now been leveraged for therapeutic benefit. This is because of their potential to reduce the effects of vomiting and nausea ensuing from anticancer radiotherapy and chemotherapy, and also from post-operative emesis that is specifically evident after procedures involving the abdomen39.
An additional therapeutic utility of the 5-HT3 receptor ligands is related to the symptomatic relief from IBS—a well-known heterogeneous condition. Although this condition is not life-threatening, it does present a significant economic and health burden. Alosetron, selective and potent 5-HT3 receptor antagonist, shows clear efficacy in decreasing the symptoms of IBS presenting with diarrhea (IBS-d). Rare occurrences of possibly fatal ischemic colitis had an impact on the marketing approval for this medication, resulting in its withdrawal. This side-effect was also recognized—again at a comparatively low incidence—in the aborted trials of cilansetron, which is another 5-HT3 receptor antagonist. This indicates that this side effect is not an “off-target” phenomenon.
The comparatively high number of patients who received 5-HT3 receptor antagonists to control emesis—without a single incidence of ischemic colitis—indicates that this side effect results from the combination of the IBS condition and 5-HT3 receptor antagonism. Most importantly, patient pressure helped the reinstatement of alosetron, although with reduced availability. However, regulatory approval exists in Japan for the use of an extremely low dose of ramosetron—the selective 5-HT3 receptor antagonist—with a maximum daily dose of 10 μg. This extremely low dose apparently lowers the occurrence of ischemic colitis by reducing the degree of blockade of the 5-HT3 receptor, albeit the efficacy levels accomplished by these low doses are a debatable topic.
An alternative pharmacological approach targeting the 5-HT3 receptor has been assessed for IBS presenting with constipation (IBS-c). In this case, the predicted prokinetic action of a 5-HT3 receptor partial agonist, DDP733, was evaluated. Regrettably, the compound showed comparatively high levels of agonist activity (intrinsic activity) such that it led to emesis in certain patients (anticipated for 5-HT3 receptor agonists with high intrinsic activity).
The potential efficacy of 5-HT3 receptor antagonists to affect behaviors that are mediated through the forebrain (for instance, cognitive dysfunction, anxiety, and alcohol-induced reward) is yet to be completely understood. In fact, the initial potential of antagonists as a treatment for these effects did not translate in reliable clinical findings. One possible explanation for this is the major variations apparent in the regional and cellular expression of the 5-HT3 receptor when a comparison was being made between humans and laboratory animals (New World primates and rodents). Fascinatingly, some effects of the 5-HT3 receptor antagonists have been detected in humans without any previous detection in animal models, such as in chronic fatigue syndrome and fibromyalgia.
The 5-HT4 Receptor
A functional 5-HT4 receptor protein—consistent with other GPCRs—emerges from one gene. However, the emerging mRNA can be alternatively spliced within the region corresponding to the C-terminus, and the region corresponding to the extracellular association between the fourth and fifth transmembrane domain. This creates 10 isoforms—5-HT4(n), 5-HT4(a-g), 5-HT4(hb), and 5-HT4(i)—although even more may be identified in the future.
5-HT4 receptor transcripts—except for the 5-HT4(d) receptor isoform—are expressed in the brain. The role of the C-terminus is to enable subcellular localization and to communicate the activation of receptors, with little impact on the pharmacology of the orthosteric site. As a result, it is no surprise that 5-HT4 receptor isoforms do not tend to vary pharmacologically, even though functional differences are obvious.
5-HT4 receptor is highly expressed in the cardiovascular tissues, gut, and brain. mRNA and protein within the brain co-localize implying a post-synaptic location. The highest levels of expression are in the basal ganglia, including the globus pallidus, substantia nigra, nucleus accumbens, putamen, caudate nucleus, cortex, and hippocampus (CA1 and subiculum)40.
The 5-HT4 receptor is positively conjugated to adenylyl cyclase through Gs, with receptor activation leading to neuronal excitability, albeit coupling to ion channels is also apparent. Furthermore, excitatory 5-HT4 receptors increase the release of several neurotransmitters including hippocampal 5-HT, nigral-striatal dopamine, and cortical acetylcholine.
It is thought that the 5-HT4 receptor plays a role in memory and learning. The majority of studies have demonstrated that activation of 5-HT4 receptors enhances performance in numerous experimental behavioral aspects of cognitive function41. The advantageous effects of the activation of 5-HT4 receptors could be mediated by facilitating the release of acetylcholine in the cerebral cortex.
Another pertinent process associated with the 5-HT4 receptor corresponds to the metabolism of amyloid precursor protein, or APP. 5-HT4 receptors encourage the secretion of a neuroprotective peptide—sAPPα—that improves memory functions in behavioral paradigms, facilitates the growth of neurons, and also ablates the cellular toxicity related to extreme glutamatergic transmission that can lead to cognitive impairment42.
Furthermore, the 5-HT4 receptor may also improve cognitive performance via depolarization of pyramidal cells within the hippocampus’ CA1 field, and thus encourage the induction of hippocampal long-term potentiation (LTP)—a cellular phenomenon considered to be ther neurophysiological basis of memory43.
In addition, the 5-HT4 receptor may possibly contribute to the generation of anxiety. 5-HT4 receptor antagonists have been shown to display anxiolytic characteristics while the 5-HT4 receptor knockout mouse displayed abnormal responses to stress, wherein stress-induced hypophagia was attenuated when compared to the wild-type strain44,45. 5-HT4 receptor antagonists—consistent with the dogma associating excessive 5-HT function with anxiety—reduce the release of hippocampal 5-HT.
There are several drug tools to activate or antagonize 5-HT4 receptors: RS 100235, SB 204070, and GR 113808 are selective high-affinity antagonists, while BIMU8, ML 10302, and RS 67506 represent non-tryptamine selective agonists. 5-methoxytryptamine—the tryptamine derivative agonist—is also a powerful yet non-selective agonist of the 5-HT4 receptor. Cisapride and other similar benzamide derivatives exhibit agonist actions. Cisapride was initially marketed as a gastro-prokinetic but was later withdrawn owing to cardiovascular side effects, which were consistent with the expression of 5-HT4 receptors in atria. Tegaserod, an additional 5-HT4 receptor agonist, created for IBS-c was withdrawn for analogous reasons.
The 5-ht5 Receptors
Two gene products—5-ht5a and 5-ht5b receptors—make up the 5-ht5 receptor subfamily. In spite of being identified almost two decades ago, they are the most poorly investigated 5-HT receptor subtypes. No conclusive evidence is available as to how they stimulate second messenger responses in native tissue, despite their structural classification as GPCRs. Due to the lack of clear physiological roles for these receptor subtypes, lower-case notation highlights their present status as purely gene products, conflicting with the upper-case notation of a receptor with recognized cellular functions in native tissues or cells.
Among the two subtypes, the 5-ht5a receptor has triggered a great deal of interest, as the human 5-ht5b receptor gene sequence could well be a pseudogene since it contains stop codons within its open reading frame. If the ensuing truncated protein was expressed, it would most probably lack functionality46. However, the rodent 5-ht5b receptor would seem to be capable of functional expression, albeit little proof has been established. Within the rat brain, 5-ht5b receptor mRNA can be found in the hippocampus, entorhinal, habenula, piriform cortices, as well as the olfactory bulb47.
The 5-ht5a receptor, within heterologous expression systems, may suppress the activity of adenylyl cyclase, probably through Gi48,49, however other investigations have failed to replicate this finding50. Other transduction processes impacted by the 5-ht5a receptor may include coupling to an inwardly rectifying potassium channel50 or increased intracellular Ca2+ mobilization51. The lack of appropriate selective ligands has limited autoradiographic study of the 5-ht5a receptor.
Expression of the 5-ht5a receptor protein in the rat brain is linked with neurons and can be seen in the horizontal nucleus of the diagonal band, locus coeruleus, raphe nuclei, hypothalamus, amygdala, with more moderate immune-reactivity in the cerebral cortex (specifically entorhinal cortex), cerebellum, pons, ventral tegmental area, substantia nigra, lateral habenula, and hippocampus. In-situ hybridization utilizing human brain tissue has shown transcripts of the 5-ht5a receptor in the cerebellum, cortex, amygdala, and hippocampus52. So far, no definitive role for native 5-ht5a receptors has been discovered, but some studies have indicated putative functions. For example, 5-ht5a receptor knockout mice exhibit improved exploratory behavior in response to a new environment46. In addition, the 5-ht5a receptor has been shown to play a role in the regulation of rodent circadian rhythm, although interpretation is complicated due to the limited number of pharmacological tools available to analyze this receptor.53
SB 699551-A, the most promising compound, shows a 30-fold selectivity for the human 5-ht5a receptor over other neuronal targets and other 5-HT receptor subtypes, apart from the serotonin transporter, which it impacts at just 10-fold higher concentrations54. Regrettably, SB 699551-A shows inter-species difference in affinity for the 5-ht5a receptor and exhibits comparatively low affinity for rodent 5-ht5a receptors (pK = 6.3), which additionally restricts the utility of this compound to probe the function of the 5-ht5a receptor via the common rodent paradigms.
The 5-HT6 Receptor
The 5-HT6 receptor is conjugated to Gs to stimulate adenylyl cyclase and displays moderate affinity for serotonin. This receptor is selectively and strongly expressed in CNS but contains species-specific patterns of expression with human and rat displaying strong expression in hippocampus and striatum. However, this expression is approximately 1/10th of the expression level in mice and litter regional variation in different regions of the mouse brain55.
While a 5-HT6 receptor knockout mouse has been developed, the phenotypic relevance is not clear, considering the low expression levels of the 5-HT6 receptor in wild-type mice as compared to human or rat56. Compared to the mouse receptor, the human and rat 5-HT6 receptors are more pharmacologically similar to each other. The 5-HT6 receptor, detected in animal models, is a potential target for cognitive improvement and perhaps weight loss57. The relatively selective 5-HT6 receptor agonists are WAY 181,187, EMD 386088, and EMDT. Several selective antagonists, including Ro 4368554, SB 258585, and SB 399885, have also been developed. The less selective ligands are also likely to have high affinity for D2 and 5-HT2A receptors. Several clinically relevant antidepressant and antipsychotic drugs also share high affinity for this receptor along with their other targets57.
The 5-HT7 Receptor
5-HT7 receptors also couple to Gs (triggering adenylyl cyclase) and are extensively distributed in the brain58. A number of splice variants with varied patterns of distribution within the CNS region have been detected59, although they do not display meaningful pharmacological distinctions in human isoforms60.
A number of atypical antidepressant and antipsychotic drugs have sufficient affinity for this receptor and will occupy it at frequently used dosages. Certain ligands that were historically linked with other 5-HT receptors also couple to 5-HT7 receptors, specifically those related to 5-HT6, 5-HT2A, and 5-HT1A receptors. The agonist 8-OH-DPAT is a specific compound that should be considered: it is a full agonist and has just approximately 10-fold higher affinity for 5-HT1A than 5-HT7 receptors.
5-HT7 receptors have been demonstrated to play a role in a wide range of physiological and behavioral processes, including vasodilation, circadian rhythmicity, and affective behavior. In the forced swim test, consistent with the pharmacological data, 5-HT7 receptor knockout mice showed reduced immobility. This suggests that this receptor blockade can create antidepressant effects. A number of moderately selective agonists have been reported, including LP 12 and AS 19; SB 269970 and SB 258719 are highly selective antagonists of 5-HT7 receptors.
The 5-HT transporter (SERT)
The 5-HT transporter (5-HTT or SERT) is a Na+/Cl– dependent biogenic amine transporter, whose family comprises the noradrenaline (NET) and dopamine (DAT) transporters61. SERT is important for the functioning of the 5-HT system and limits the neurotransmission of the 5-HT by removing synaptic neurotransmitter via transport across the presynaptic membrane62. After the original sequencing of rat SERT63, follow-up studies have suggested that the functional complex can exist as an oligomer64,65.
Within the brain, SERT is found throughout 5-HT neurons, and therefore shows a distribution at the protein level that almost matches the areas receiving 5-HT neuron innervation. The protein provides a phenotypic marker for 5-HT neurons66. Consistently, studies performed on in situ hybridization reveal that SERT transcript expression is linked with the cell bodies of 5-HT neurons67. However, in the developing mouse brain, transporter expression occurs temporarily in glutamatergic thalamocortical afferents that are incapable of synthesizing 5-HT68,69. Therefore, these neurons may sequester 5-HT, allowing the afferents to mediate serotonergic transmission during the course of brain development.
More than a single form of SERT protein seems to be present in vivo. Using a pair of selective antibodies, raised against varied epitopes within the N- and C-terminus, Shigematsu et al performed immunohistochemical studies on the mouse brain70. The team noticed that immunoreactivity with the N-terminal antibody was not present in the CA3 field of the hippocampus, while the C-terminal antibody indicated the expression of SERT in this area. This suggests that variable N-terminal domains might be present in SERT, possibly through alternative splicing of exon 1. More molecular diversity seems to be evident in human immune cells, in which SERT may function to deliver 5-HT to other immune cells across the immunological synapse71.
The efficacy of an array of antidepressant drugs, specifically the selective serotonin reuptake inhibitors (SSRIs), has made it possible to describe the physiological roles of SERT in the brain. It is unquestionable that the transporter has an impact on depression, although its accurate function is still a debatable topic. More evidence arises from the genetic difference that takes place upstream of the SERT coding sequence: the 5-HTT gene-linked polymorphic region (5-HTTLPR). A range of repeated units integrated inside this sequence creates a promoter region that regulates the expression of SERT72,73. Within this region, one common polymorphism is a 44 base pair deletion, indicated as a short form (S) for the gene, together with variations of a long form (LA and LG). The short form allele lowers the expression and function of SERT in relation to the long forms72,74. However, it has been reported that LG may lead to SERT expression similar to the short form variant75, and the short form allele may not be related to reduced SERT levels in the adult brain76, further complicating the research field. Even if one short form allele is present in individuals, it predisposes them to depressive episodes.
In further support from in vivo imaging, expression of SERT is reduced within the brainstem77, amygdala and midbrain78 in patients suffering from depression. Several reports associate the expression of SERT with the brains of suicide victims, although this area continues to be a controversial topic79. However, SERT knockout mice show behavioral abnormalities in relation to anxiety and depression80,81.
Although SERT is a molecular therapeutic target, it is also a target for numerous drugs of abuse, such as cocaine and MDMA (ecstasy). For instance, MDMA blocks the reuptake of 5-HT and increases its release82,83. While cocaine is mainly believed to act upon DAT, SERT interaction seems to contribute to cocaine’s rewarding actions84.
The 5-HT receptor research field—right from the original discovery of serotonin in the mid-20th century—continues to expand on both commercial and scientific levels. Over the last six decades, significant pharmacological and physiological processes involving 5-HT transporter and 5-HT receptors have been discovered. The successive discovery of the six classes of G-protein coupled 5-HT receptors (5-HT1,2,4–7) and their subclasses, together with the ligand-gated ion channel 5-HT3, has offered an interesting research platform that shows potential for upcoming drug discovery. 5-ht1e and 5-ht5 receptors are comparatively uncharacterized and the discovery of selective ligands for these receptors may help in interpreting their functions in vivo.
One major issue in this area has been the lack of adequately selective ligands to detect the relative contribution of various serotonin receptors to serotonin-mediated complex physiological and behavioral phenomena. As the latest pharmacological and molecular tools become available, targeting specific 5-HT receptors should result in the development of compounds of therapeutic value that will decrease the possibility for unwanted side effects. A new generation of serotonergic drugs that can be useful as antiemetic, antidepressant, precognitive, and antipsychotic treatments could be developed in the future. It can be expected that 5-HT receptor studies will continue to advance and yield interesting outcomes in the near future.
This white paper was based on the original work of:
Nicholas M. Barnes: Cellular and Molecular Neuropharmacology Research Group, Section of Neuropharmacology and Neurobiology, Clincal and Experimental Medicine, The Medical School, University of Birmingham, UK. Email: [email protected]
John F. Neumaier: Department of Psychiatry, University of Washington, Seattle, USA. Email: [email protected]
- Barnes and Sharp (1999) Neuropharmacology 38 1083.
- Berthouze et al. (2005) FEBS Lett. 579 2973.
- Stamford et al. (2000) Trends Neurosci. 23 459.
- Ramboz et al. (1998) Proc.Natl.Acad.Sci. 95 14476.
- Parks et al. (1998) Proc.Natl.Acad.Sci. 95 10734.
- Bruinvels et al. (1994) Neuropharmacology 33 367.
- Clark and Neumaier (2001) Neurosci.Biobehav.Rev. 28 565.
- Sari (2004) Neurosci.Biobehav.Rev. 28 565.
- Bonaventure et al. (1998) Neuroscience 82 469.
- Trillat et al. (1997) J.Neurochem. 69 2019.
- Pineyro et al. (1995) Neuroreport 7 353.
- Bai et al. (2004) J.Pharmacol. 484 127.
- Klein and Teitler (2009) J.Neurochem 109 268.
- Shepheard et al. (1999) Cephalalgia 19 851.
- Gaddum and Picarelli (1957) Chemother. 12 323.
- Hannon and Hoyer (2008) Behav.Brain.Res. 195 198.
- Berg et al. (2005) Trends.Pharmacol.Sci 26 625.
- Berg et al. (2008) Neuropharmacology 55 969.
- Giorgetti and Tecott (2004) Eur.J.Pharmacol. 488 1.
- Fletcher et al. (2009) Neuropharmacology 57, 259-267.
- Barnes et al. (2009) Neuropharmacology 56 273.
- Boess et al. (1995) J.Neurochem. 64 1401.
- Davies et al. (1999) Nature 397 359.
- 24. Dubin et al. (1999) J.Biol.Chem. 274 30799.
- Machu and Harris (1994) J.Pharmacol.Exp.Ther. 271 898.
- Suzuki et al. (2002) Anesthesiology 96 699.
- Parker et al. (1996) Trends.Pharmacol.Sci 17 95.
- Stevens et al. (2005) J. Pharmacol.Exp.Ther. 314 338.
- Pratt et al. (1990) Trends Pharmacol. Sci. 11 135.
- Barnes et al. (1989a) J.Neurochem. 53 1787.
- Lochner and Lummis (2010) Biophys.J. 98 1494.
- Das and Dillon (2005) J. Pharmacol.Exp.Ther. 314 320.
- Rojas et al. (2010) Eur.J.Pharmacol. 626 193.
- De Deurwaerdere et al. (1998) J. Neurosci. 18 6528.
- Martin et al. (1992) Br J Pharmacol. 106 139.
- Barnes et al. (1989b) Nature 338 762.
- Diez-Ariza et al. (2002) Brain Res. 956 81.
- Morales and Bloom (1997) J. Neurosci. 17 3157.
- Ikeda et al. (2005) Eur. J. Cancer Care (Engl). 14 435.
- Varnäs et al. (2003) Eur. Neuropsychopharmacology 13 228.
- Bockaert et al. (2004) Curr.Drug.Targets.CNS.Neurol. Disord. 3 39.
- Lezoualc’h and Robert (2003) Exp.Gerontol. 38 159.
- Chapin et al. (2002) Neurosci.Lett. 324 1.
- Kennett et al. (1997) Neuropharmacology 36 707.
- Compan et al. (2004) J. Neurosci. 24 412.
- Grailhe et al. (1999) Neuron. 22 581.
- Matthes et al. (1993) Mol.Pharmacol. 43 313.
- Hurley et al. (1998) Br.J.Pharmacol. 124 1238.
- Francken et al. (1998) Eur. J. Pharmacol. 361 299.
- Grailhe et al. (2001) Eur.J.Pharmacol. 418 157.
- Noda et al. (2003) J.Neurochem. 84 222.
- Pasqualetti et al. (1998) Mol.Brain Res. 56 1.
- Sprouse et al. (2004) Synapse 54 111.
- Thomas (2006) Pharmacol. Ther. 111 707.
- Hirst et al. (2003) Mol. Pharmacol. 64 1295.
- Bonasera et al. (2006) Neuropsychopharmacology 31 1801.
- Mitchell and Neumaier (2005) Pharmacol.Ther. 108 320.
- Neumaier et al. (2001) J.Chem.Neuroanatomy 21 63.
- Heidmann et al. (1998) Neuropharmacology 37 1621.
- Krobert and Levy (2002) Br.J.Pharmacol. 135 1563.
- Masson et al. (1999) Pharmacol. Rev. 51 439.
- Rudnick and Clark (1993) 1144 249.
- Blakely et al. (1991) Nature 354 66.
- Ramamoorthy et al. (1993) Placenta 14 449.
- Kilic and Rudnick (2000) Proc.Natl.Acad.Sci. USA 97 3106.
- Qian et al. (1995) J. Neurosci. 15 1261.
- Fujita et al. (1993) Neurosci.Lett. 162 59.
- Lebrand et al. (1996) Neuron 17 823.
- Bruning and Liangos (1997) Acta.Histochem. 99 117.
- Shigematsu et al. (2006) Brain Res. 1075 110.
- 71. Chamba et al. (2008) J.Neuroimmunol. 204 75.
- Lesch et al. (1996) Science 274 1527.
- Greenberg et al. (1999) Am.J.Med.Genet. 88 83.
- Little et al. (1998) Am.J.Psychiatry 155 207.
- Hu et al. (2006) Am.J.Hum.Genet. 78 815.
- Parsey et al. (2006) Am.J.Psychiatry 163 48.
- Malison et al. (1998) Biological Psychiatry 44 1090.
- Parsey et al. (2006b) Am.J.Psychiatry 163 52.
- Purselle and Nemeroff (2003) Neuropsychopharmacology 28 613.
- Lira et al. (2003) Biol.Psychiatry 54 960.
- Zhao et al. (2006) Neuroscience 140 321.
- Pletscher et al. (1963) Life Sciences 2 828.
- Rudnick and Wall (1992) Proc.Natl.Acad.Sci. USA 89 1817.
- Rocha et al. (1998) Nature Neurosci. 1 132.
About Tocris Bioscience
Tocris Bioscience is your trusted supplier of high-performance life science reagents, including receptor agonists & antagonists, enzyme inhibitors, ion channel modulators, fluorescent probes & dyes, and compound libraries. Our catalog consists of over 4,500 research tools, covering over 400 protein targets enabling you to investigate and modulate the activity of numerous signaling pathways and physiological processes.
We have been working with scientists for over 30 years to provide the life science community with research standards, as well as novel and innovative research tools. We understand the need for researchers to trust their research reagents, which is why we are committed to supplying our customers with the highest quality products available, so you can publish with confidence.
Tocris is part of the protein sciences division of Bio-Techne, which also includes the best in class brands R&D Systems, Novus Biologicals, ProteinSimple, and Advanced Cell Diagnostics. Bio-Techne has united these brands to provide researchers with a full portfolio of research reagents, assays, and protein platforms. For more information on Bio-Techne and its brands, please visit bio-techne.com.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices, and treatments.